Literature DB >> 7603042

Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Protective effects of ACE inhibition.

C Sassy-Prigent1, D Heudes, S Jouquey, D Auberval, M F Belair, O Michel, G Hamon, J Bariety, P Bruneval.   

Abstract

BACKGROUND: Glomerulosclerosis is the main renal lesion complicating diabetes in humans and in experimental models. Angiotensin I-converting enzyme (ACE) inhibitors are effective in preventing the development of diabetic nephropathy. Incipient glomerular lesions were explored in streptozotocin-diabetic rats at a stage when glomerulosclerosis was not yet established. The modulation of such early glomerular lesions by a new ACE inhibitor (Trandolapril (T) at high or low doses was assessed. EXPERIMENTAL
DESIGN: Five groups of rats were designed as follows: (a) nondiabetic control rats, (b) diabetic rats, (c) diabetic rats treated with 0.1 mg/kg/day of T, (d) diabetic rats treated with 1 mg/kg/day of T, and (e) nondiabetic rats treated with 1 mg/kg/day of T. The rats were killed at 1, 3, and 6 months after the beginning of the treatment. The kidneys were studied using a powerful morphometric technique at optical microscopic level with an image analyzer to measure the following glomerular parameters to assess the development of incipient glomerular lesions: (a) total glomerular surface area, (b) glomerular tuft surface area, (c) mesangial surface area, (d) ratio of the mesangial surface area to the glomerular tuft surface area, and (e) mean thickness of the Bowman's capsule. In parallel, albuminuria was measured.
RESULTS: The results showed the development of glomerular hypertrophy in parallel with the increase in glomerular mesangial domain and in albuminuria with diabetes. They also demonstrated that ACE inhibitor given at a high dose is significantly effective in reducing glomerular hypertrophy and the expansion of the mesangial domain. ACE inhibitor given at a low dose tended to reduce glomerular hypertrophy and the expansion of the mesangial domain. Furthermore, ACE inhibitor at both doses completely abolished the albuminuria increase, maintaining the levels of albuminuria within the range of young nondiabetic rats.
CONCLUSIONS: Using morphometric image analysis, incipient glomerular changes can be detected before glomerulosclerosis is patent in experimental diabetes. Moreover, they can be easily and reliably quantified by this technique, allowing comparison among experimental groups. These changes can be prevented by ACE inhibition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603042

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  Protective effect of herbomineral formulation (Dolabi) on early diabetic nephropathy in streptozotocin-induced diabetic rats.

Authors:  Mirza A Baig; Vikas B Gawali; Rajesh R Patil; Suresh R Naik
Journal:  J Nat Med       Date:  2011-11-25       Impact factor: 2.343

2.  Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes.

Authors:  Ran Choi; Bo Hwan Kim; Jarinyaporn Naowaboot; Mi Young Lee; Mi Ri Hyun; Eun Ju Cho; Eun Soo Lee; Eun Young Lee; Young Chul Yang; Choon Hee Chung
Journal:  Exp Mol Med       Date:  2011-12-31       Impact factor: 8.718

3.  Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.

Authors:  M Yamamoto; M Fukui; I Shou; L N Wang; K Sekizuka; S Suzuki; I Shirato; Y Tomino
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  Urinary protein profiles in a rat model for diabetic complications.

Authors:  Daniela M Schlatzer; Jean-Eudes Dazard; Moyez Dharsee; Rob M Ewing; Serguei Ilchenko; Ian Stewart; George Christ; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-06-04       Impact factor: 5.911

5.  Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase.

Authors:  Yasuhiro Hashimoto; Shin-Ichiro Yamagishi; Hiroki Mizukami; Chihiro Yabe-Nishimura; Sun Woo Lim; H Moo Kwon; Soroku Yagihashi
Journal:  J Diabetes Investig       Date:  2011-04-07       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.